The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
Site Search
Showing 51 - 60 of 560 results
News
|
|
3 min read
This year, Cystic Fibrosis Advocates inspired new champions in Washington, D.C. and in state capitols across the country to take action on critical CF-related issues.
News
|
|
2 min read
Press Release
|
|
6 min read
Press Release
|
|
4 min read
Press Release
|
|
3 min read
Nationwide Effort to Instill Best Practices for Cystic Fibrosis Care is Honored for Excellence
Press Release
|
|
3 min read
News
|
|
2 min read
Press Release
|
|
3 min read